Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells

Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer

(2009) Oronza Antonietta Botrugno et al.   CANCER LETTERS

Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors

(2009) Elizabeth M. Algar et al.   PLoS One

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors in cancer therapy

(2008) Min-Jung Lee et al.   CURRENT OPINION IN ONCOLOGY

Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor

(2008) Susan N. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors

(2008) Sharon L. Gardner et al.   PEDIATRIC BLOOD & CANCER